. Author manuscript; available in PMC: 2022 Nov 15.

Published in final edited form as: Cancer. 2021 Aug 3;127(22):4213–4220. doi: 10.1002/cncr.33814

Table 2.

Outcomes of propensity of matched patients with relapsed or refractory acute myeloid leukemia who received 10-day decitabine with venetoclax (DEC10-VEN), and intensive chemotherapy (IC)

Outcomes	DEC10-VEN (N=65)	IC (N=130)	OR / HR (95% CI)	Stratified p
Overall response rate (ORR)	37 (60)	36 (28)	3.28 (1.73, 6.23)	<.001
CR/CRi	27 (42)	30 (23)	2.52 (1.26, 5.03)	.009
CR	15 (23)	22 (17)	1.44 (0.70, 2.94)	.320
CRi	12 (19)	8 (6)	3.56 (1.32, 9.61)	.012
MLFS	10 (15)	6 (5)	3.33 (1.21, 9.17)	.020
MRD negativity	18 (28)	17 (13)	2.48 (1.17, 5.24)	.017
Refractory	22 (35)	71 (55)	0.46 (0.25, 0.84)	.011
Inevaluable¹	1 (2)	1 (1)	2.00 (0.13, 31.98)	.624
Relapse	19 (51)	17 (47)	0.75 (0.24, 2.38)	.630
30-day mortality	5 (8)	16 (12)	0.58 (0.2, 1.70)	.322
60-day mortality	8 (12)	35 (27)	0.40 (0.18, 0.91)	.029

Results reported as n (%), n/N (%). ORR = CR+CRi+MLFS, CR = complete remission; CRi = CR with incomplete hematologic recovery, MLFS = morphologic leukemia-free state. MRD = minimal residual disease evaluated using multiparametric flow cytometry validated to a sensitivity level of 0.1–0.01%; OR = odds ratio; HR = hazard ratio, NA= not applicable,

^1.

One patient was taken off DEC10-VEN after receiving only 2 days of therapy and another patient was taken off IC after 1 day off therapy due to adverse event